Hearing loss: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 0
• PD-1 0
• SGLT2 0
• ABL1 0
• AMPK 0
• CGRP 0
• ERK 0
• JAK 0
• mTOR 0
• NLRP3 0
• SHP2 0
• STAT3 0
• STING 0
• VEGF 0

1750 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  REstoring VIsion via native-Code-Aligned Neurostimulation (REVICAN)

  Univerzita Karlova· Praha 1, Csehország· EU contribution 731 460 EUR· until 2030. szept.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Visual Hearing for Context-Aware Cognitive Audio Technology (WeHear)

  Danmarks Tekniske Universitet· Kongens Lyngby, Dánia· EU contribution 5 411 208 EUR· until 2029. aug.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Unlocking bio-inspired machine hearing and accelerating personalized hearing technologies (InSilicoEars)

  Universiteit Gent· Gent, Belgium· EU contribution 1 999 712 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Watts in my ear? Unravelling the power source of mammalian hearing. (ActivEAR)

  Universidad Autonoma de Madrid· Madrid, Spanyolország· EU contribution 1 923 556 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Advancing a scalable and multifactorial exosome therapy to address the unmet needs of drug-induced hearing loss (EXO-OTOProtect)

  Exogenus Therapeutics Sa· Cantanhede, Portugália· EU contribution 500 000 EUR· until 2028. febr.

5 of 21 running projects, newest first. Listed amounts together: 41,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Apple Hearing Study

  NCT04172766· Apple Inc.· Frissítve: 2026. nov. 2.

  “sponsor termination of research funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Oral Statins and Protection From Hearing Loss

  NCT04826237· Northwestern University· Frissítve: 2026. okt. 29.

  “Insufficient funding”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language

  NCT06902753· Poitiers University Hospital· Frissítve: 2026. okt. 27.

  “Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

  NCT06354010· Sensorion· Frissítve: 2026. okt. 26.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Exploration of the Functional Effect of Modified Gain Precalculation on Soft Speech Intelligibility

  NCT07388784· Sebastian Griepentrog· Frissítve: 2026. júl. 27.

  “Despite heavy recruiting efforts not enough participants could be found”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss

  NCT02779192· Sound Pharmaceuticals, Incorporated· Frissítve: 2026. jún. 3.

  “Study did not start”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

  NCT01451853· Sound Pharmaceuticals, Incorporated· Frissítve: 2026. jún. 3.

  “Study did not start”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment

  NCT07526428· Sonova AG· Frissítve: 2026. máj. 29.

  “Corrupted data”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  The Performance of Different Sound Paths in Adult NeuroZti CI-users

  NCT07033130· Cochlear· Frissítve: 2026. máj. 22.

  “Preliminary feasibility outcomes from 4 enrolled participants met expectations. Following a serious adverse event that is unrelated to the investigational device/procedures, a risk-benefit assessment determined additional enrolment was not justified.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss

  NCT06437054· Seoul National University Hospital· Frissítve: 2026. máj. 22.

  “This study was withdrawn before enrollment due to challenges in participant recruitment. A revised study protocol will be initiated under a new research project.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Evaluating a Noise Reduction Algorithm With Cochlear Implant Users

  NCT05805384· NYU Langone Health· Forrás

• Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss

  NCT07774728· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Forrás

• Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness

  2024-510798-84-00· Helse Bergen HF· Forrás

• Audiological Rehabilitation of Children With Unilateral Hearing Loss

  NCT07911852· Father Flanagan's Boys' Home· Forrás

• Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

  NCT05776459· AudioCure Pharma GmbH· Forrás

• Barriers and Facilitators to OTC Hearing Aids Success

  NCT06499805· Yu-Hsiang Wu· Forrás

• New Hearing Aid Users and Their Social Participation

  NCT07866586· University of Nottingham· Forrás

• Investigating Auditory Processing in the Users of Auditory Brainstem and Cochlear Implants

  NCT05810220· NYU Langone Health· Forrás

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Forrás

• Effectiveness of Virtual Reality vs Show-Do Technique on Dental Anxiety in Children With Hearing Impairment

  NCT07245030· October University for Modern Sciences and Arts· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Organoids 12
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 6
• Gene Expression Profiling 18
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 6
• Exome Sequencing 75
• Proteomics 10
• Metabolomics 9
• Mass Spectrometry 1
• Immunohistochemistry 12
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 162
• Machine Learning 37
• Deep Learning 20
• Cohort Studies 95
• Genome-Wide Association Study 23

• Emerging Therapies for Genetic Deafness: The Rise of Precision Gene Editing.

  Ear Hear, 2026. okt.

• Gene editing of the GJB2 locus in porcine embryos using CRISPR/Cas9 and cytosine base editors: toward a model of congenital deafness.

  Sci Rep, 2026. ápr.

• Multi-omic analyses identify molecular targets of Chd7 that contribute to CHARGE syndrome model phenotypes.

  Dis Model Mech, 2026. márc.

• Adaptable, quantitative CRISPR/Cas12a-based assay for cytomegalovirus DNA in infant saliva.

  Sci Rep, 2026. márc.

• A porcine congenital deafness model with unconditional knockout of GJB2 generated by CRISPR/Cas9 genomic editing.

  Hear Res, 2026. jan.

• CRISPR-free RNA base editing mediated PTC-readthrough restores hearing in mice with Otof nonsense mutation.

  Nat Commun, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.